Observational studyEuropean journal of pediatrics2026
Evaluation of vaccine immunity against tetanus, hepatitis B, measles, mumps, rubella and varicella, in migrant adolescents aged 13 to 18 years arriving in Geneva in 2023.
Observational study in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent surge in unaccompanied minor asylum seekers (UMAS) arriving in Switzerland presents significant public health challenges, particularly regarding immunization. Many of these adolescents lack vaccination documentation, requiring catch-up vaccination strategies. This study aimed to evaluate immunity against tetanus, hepatitis B, measles, mumps, rubella and varicella among UMAS upon arrival in Switzerland, to optimize vaccination strategies, and provide protection. This retrospective observational study included 100 UMAS patients followed at Geneva University Hospitals in 2023. Patients received a booster of diphtheria-tetanus-pertussis-inactivated poliovirus vaccine (dTPa-IPV) at the first visit at HUG, followed by serology testing one month later during the second visit. Immunity was defined based on established antibody thresholds. Data on demographics, vaccination history since arrival in Switzerland, and serology for tetanus, hepatitis B, measles, rubella, mumps, and varicella were collected from medical records. Among the 100 UMAS included, 83% originated from Afghanistan, 6% from Burundi, 4% from Somalia, 2% from Eritrea, and the remainder from other countries. The median age was 16 years, and 94% were male. Serological testing on arrival showed that 83% were immune to varicella, whereas immunity to measles was lower at 66%. Immunity rates were higher for mumps (90%) and rubella (89%). Only 22% had protective anti-HBs levels. After administration of a single dTPa-IPV booster, 89% achieved protective tetanus IgG concentrations at one-month follow-up.Conclusion: A substantial proportion of UMAS lacked immunity to measles, hepatitis B, and, to a lesser extent, tetanus and varicella, underscoring the need for systematic catch-up vaccination. Based on these findings, a pragmatic two-visit strategy appears optimal: Visit 1: administer MMR (or MMRV), Tdap-IPV, and hepatitis B vaccines to all UMAS; Visit 2 (after 1 month): repeat MMR (or MMRV) and perform tetanus and hepatitis B serology to guide additional doses. This streamlined approach maximizes early protection while remaining feasible within high-income healthcare settings.
Indexed as
Identifiers
41817808What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.